During the past decade, Kagawa University Hospital conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 17 clinical trials were completed, i.e. on average, 48.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 14 clinical trials were completed. i.e. 73.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kagawa University Hospital" #1 sponsor was "Boehringer Ingelheim" with 5 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Mitsubishi Tanabe Pharma America Inc." with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kagawa University Hospital" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator and "Alpha-A, Inc." with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Kagawa University Hospital" are "Alzheimer Disease" (4 trials), "Prostatic Neoplasms" (3 trials), "Systemic Lupus Erythematosus" (3 trials), "ALS" (2 trials) and "Axial Spondyloarthritis" (2 trials). Many other conditions were trialed in "Kagawa University Hospital" in a lesser frequency.

Most popular intervention types in "Kagawa University Hospital" are "Drug" (37 trials), "Other" (4 trials), "Device" (3 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Baricitinib" (3 trials), "Docetaxel" (3 trials), "Faricimab" (3 trials) and "MT-1186" (3 trials). Other intervention names were less common.

The vast majority of trials in "Kagawa University Hospital" are 40 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Kagawa University Hospital". undefined are not yet recruiting, 9 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Kagawa University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Kagawa University Hospital, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Kagawa University Hospital has several departments that took part in Clinical trials: "Kagawa University Faculty of Medicine" - 4 trials